EMR · NYSE
Consensus is $1.81 EPS for Sep 2026 across 6 estimates, ranging $1.76 to $1.84.
No consensus figures are available, so the quarter cannot be assessed against market expectations. Emerson reported $4.87B of revenue and $0.72B of net income for the quarter ended June 30, 2026, up sequentially from $4.56B of revenue and $0.62B of net income in the second quarter, and above $4.86B of revenue and $0.64B of net income in the fourth quarter of fiscal 2025. The supplied filing extract does not include the 2026 segment sales, earnings, or margin table, so it does not establish which businesses carried or dragged performance or explain the quarter's margin outcome. The prior-year presentation shows Intelligent Devices as the largest earnings contributor at $597M, versus $245M for Software & Systems and $103M for Safety & Productivity, but those figures were reclassified to conform to the new fiscal 2026 structure. No explicit quarterly revenue growth rate or operating margin is provided.
No revenue, earnings, margin, or capital-expenditure guidance was given in the supplied material. Management did provide selected forward-looking indicators: backlog was approximately $9.6B at June 30, 2026, and approximately 75 percent of remaining performance obligations is expected to convert to revenue over the next 12 months, with the remainder substantially over the following two years. The company expects fiscal 2026 restructuring expense and related costs to be approximately $185, including costs to complete actions initiated during the first nine months. These disclosures provide visibility into order conversion and restructuring spending but do not replace a full-period financial outlook.
